← All diseases

Disease Atlas / Disease detail

Spinal Muscular Atrophy

This is educational material explaining the key aspects of the causes, symptoms, diagnosis, management, and interpretation of research for Spinal Muscular Atrophy.

spinal muscular atrophy

MONDO:0001516Public QA completeSource-bound · 5

Disease at a glance

Start with the essentials, then explore the patient and research views.

Public revision · b6079975800c

Disease Category
Spinal Muscular Atrophy (SMA) is a group of genetic diseases characterized by the damage or loss of motor neurons in the spinal cord and lower part of the brain, causing weakness and atrophy of voluntary muscles.
Core mechanism
Most SMA cases are associated with changes in the SMN1 gene, which produces a protein necessary for motor neurons, while rare forms can occur due to other genetic changes.
Main causes · Related factors
When changes in the SMN1 gene lead to a deficiency in the required protein, motor neurons lose function and are lost, resulting in decreased muscle movement and strength.
Representative patterns
Representative features include decreased muscle strength in the limbs and trunk, reduced movement, and difficulty maintaining posture and walking; functions such as speaking, swallowing, and breathing may also be affected.
Individual differences
The timing of onset and severity vary depending on the type of SMA and the individual's genetic and clinical characteristics, and parental genetic changes can be transmitted to offspring.
Diagnosis
Symptoms can begin from infancy through adulthood, and during the disease course, joint contractures, scoliosis, recurrent respiratory problems, and breathing/swallowing impairments may develop.
Management
Diagnosis focuses on evaluating developmental status and family history, neurological examination, and genetic testing, with electromyography/nerve conduction studies or muscle biopsy considered as adjunctive options if necessary.
Treatment/Research Status
Since it may be difficult to distinguish from other neuromuscular diseases based on clinical presentation alone, genetic testing results should be interpreted in conjunction with the testing panel and methodology, and SMA should not be definitively excluded based on negative results alone.
Evidence Reading
Management is carried out through a multidisciplinary approach that assists muscle strength and function and prevents complications related to respiration, nutrition, and swallowing, and may include rehabilitation therapy, assistive devices, and nutritional and respiratory support.
Key Precautions
Treatment focuses on assisting motor neuron function and managing symptoms and complications, and drugs that help protein production or gene therapy may be considered in specific patients.

For patients and families

A structured guide for understanding the disease and preparing for clinical conversations.

At a Glance

Spinal Muscular Atrophy (SMA) is a group of genetic diseases characterized by the damage or loss of motor neurons in the spinal cord and lower part of the brain, causing weakness and atrophy of voluntary muscles.

Representative features include decreased muscle strength in the limbs and trunk, reduced movement, and difficulty maintaining posture and walking; functions such as speaking, swallowing, and breathing may also be affected.

How the Disease Works

Most SMA cases are associated with changes in the SMN1 gene, which produces a protein necessary for motor neurons, while rare forms can occur due to other genetic changes.

When changes in the SMN1 gene lead to a deficiency in the required protein, motor neurons lose function and are lost, resulting in decreased muscle movement and strength.

Patterns Vary by Person

The timing of onset and severity vary depending on the type of SMA and the individual's genetic and clinical characteristics, and parental genetic changes can be transmitted to offspring.

Broad framework of diagnosis and management

Symptoms can begin from infancy through adulthood, and during the disease course, joint contractures, scoliosis, recurrent respiratory problems, and breathing/swallowing impairments may develop.

Diagnosis focuses on evaluating developmental status and family history, neurological examination, and genetic testing, with electromyography/nerve conduction studies or muscle biopsy considered as adjunctive options if necessary.

Current stage of treatment

Since it may be difficult to distinguish from other neuromuscular diseases based on clinical presentation alone, genetic testing results should be interpreted in conjunction with the testing panel and methodology, and SMA should not be definitively excluded based on negative results alone.

Management is carried out through a multidisciplinary approach that assists muscle strength and function and prevents complications related to respiration, nutrition, and swallowing, and may include rehabilitation therapy, assistive devices, and nutritional and respiratory support.

Treatment focuses on assisting motor neuron function and managing symptoms and complications, and drugs that help protein production or gene therapy may be considered in specific patients.

How to read clinical trials

Clinical trials must be interpreted by verifying the research type, subjects, evaluation indicators, and follow-up period, and the mere registration or completion of observational studies cannot be used to determine treatment efficacy, safety, or standard of care.

Points to verify in clinical encounters

In clinical practice, it is important to confirm the age of onset and motor development, respiratory/swallowing/nutritional status, family history and the scope of genetic testing, current use of rehabilitation/assistive devices, and recent functional changes and treatment goals.

Medical Guide

This material is for educational purposes and does not replace individual diagnosis or treatment.

Evidence and sources

A trial registry status does not establish efficacy or regulatory approval.